Glioblastoma Multiforme of Brain Clinical Trial
Official title:
Multi Peptide Vaccination With Pam3Cys-GDPKHPKSF (XS15) as an Immunomodulator in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed HLA-A2-positive MGMT-methylated Glioblastoma
Newly diagnosed HLA-A2-positive MGMT-methylated glioblastoma patients will be vaccinated with a Multi peptide vaccination with Pam3Cys-GDPKHPKSF (XS15) as an immunomodulator in addition to standard postoperative radiation therapy and temozolomide chemotherapy to assess immunogenicity, efficacy, safety of the combination of multipeptide vaccination and the immune modulator XS15 emulsified in Montanide ISA 51 VG
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03657576 -
Trial of C134 in Patients With Recurrent GBM
|
Phase 1 | |
Recruiting |
NCT05685004 -
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)
|
Phase 2/Phase 3 | |
Recruiting |
NCT05076513 -
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
|
Early Phase 1 | |
Active, not recruiting |
NCT03665545 -
Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma
|
Phase 1/Phase 2 | |
Completed |
NCT02474966 -
Effect of Deep TMS on the Permeability of the BBB in Patients With Glioblastoma Multiforme: a Pilot Study
|
Phase 2 | |
Active, not recruiting |
NCT02137759 -
MRSI to Predict Response to RT/TMZ ± Belinostat in GBM
|
Phase 2 | |
Enrolling by invitation |
NCT03170141 -
Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme
|
Phase 1 | |
Recruiting |
NCT04869449 -
Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas
|
Early Phase 1 | |
Recruiting |
NCT03633552 -
Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma
|
Phase 3 | |
Not yet recruiting |
NCT05095441 -
A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma
|
Phase 1 | |
Completed |
NCT00003456 -
Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT03047473 -
Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme
|
Phase 2 | |
Enrolling by invitation |
NCT05116137 -
The Impact of Resistance ExerciSe on Muscle Mass in GlioblaSToma Survivors
|
N/A | |
Recruiting |
NCT05627323 -
CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma
|
Phase 1 | |
Active, not recruiting |
NCT04968366 -
Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery
|
Phase 1 | |
Suspended |
NCT04222309 -
Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)
|
Phase 1 | |
Not yet recruiting |
NCT06186440 -
Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated Glioblastoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06273176 -
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
|
||
Recruiting |
NCT06283927 -
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
|
||
Recruiting |
NCT06146725 -
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
|